Pharmaceuticals
Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-18 08:00
2640
Promising Efficacy of AT101 CAR-T for Blood Cancer
SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...
2023-04-18 02:00
2013
Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions
SHANGHAI, April 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases, today released its 2022 annual report. Whil...
2023-04-17 18:30
2384
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announces today thatBassem Elmankabadi, M.D. joins Foresee as a Senior Vice President of Clinical Development. Dr. Bassem Elmankabadi is a Board Certified Surgeon with over 17 years of clinical backg...
2023-04-17 16:50
2418
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-17 08:20
3531
Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT
* Study met both primary and all key secondary endpoints * Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in 1.0% MH004 Cream-treated group compared to -46.7% in vehicle group * 79.6% individuals treated with 1.0% MH004 Cream achieved EASI-75 c...
2023-04-14 19:00
6950
Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults
NANJING, China, April 13, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-71...
2023-04-14 01:15
2445
Viva Biotech Attended SAPA-China
HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development ofChina's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held inChengdu, Sichuan. Viva Bi...
2023-04-13 11:33
2536
Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis, cancer, and inflammation, announced it has dosed the first patient in its Phase 2a clinical study...
2023-04-13 06:00
2454
Standigm announces Younsung Choo as chief executive officer
Former LG life Sciences exec and long-time Standigm advisor brings extensive
experience in pharmaceuticals and project management
SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm
2023-04-13 00:07
2493
GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications
YONGIN, South Korea, April 11, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, today announced the publication of a new study inNature Communications, showcasing the company's novel AI-based liquid biopsy technology. The study highlights the unprecedented accura...
2023-04-12 11:06
2030
Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia
SINGAPORE, April 11, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with CTTQ-Akeso ( Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso)（jointly established by Akeso, Inc. (9926.HK, Akeso) and Chia Tai Tianqing Pharmaceutical Group Co...
2023-04-12 06:00
2850
OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023
NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...
2023-04-11 20:00
1761
Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"
SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...
2023-04-10 20:18
2500
China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeut...
2023-04-07 16:34
4798
Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")
SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainlandChina. Ensifentrine is a fi...
2023-04-07 10:00
2606
BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer
CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 /PRNewswire/ --
BIORCHESTRA
2023-04-05 20:00
2919
Biosion Initiates Phase II Clinical Trial of BSI-045B in Atopic Dermatitis
NEWARK, Del. and NANJING, China, April 4, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced that it has successfully opened an IND following review by the U.S. Food and Drug Administration toinitiate a Phase 2 clinical trial of BS...
2023-04-04 20:50
2391
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...
2023-04-04 20:00
3177
GC Cell and New Management Embarking on a New Chapter
* Securing future growth engine by scouting global talents; AGM resolved new CEOJames Park and CTO Ho-won Kim as internal directors * Setting business goals focusing on change and growth * Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN,South Korea, April 3...
2023-04-03 16:47
2761
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 309 media titles]
2026-02-03 11:00
Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 302 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35